"Hemoglobin, Sickle" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An abnormal hemoglobin resulting from the substitution of valine for glutamic acid at position 6 of the beta chain of the globin moiety. The heterozygous state results in sickle cell trait, the homozygous in sickle cell anemia.
MeSH Number(s)
D12.776.124.400.463.588
D12.776.422.316.762.426.588
Concept/Terms
Deoxyhemoglobin S- Deoxyhemoglobin S
- S, Deoxyhemoglobin
- Deoxygenated Sickle Hemoglobin
- Hemoglobin, Deoxygenated Sickle
- Sickle Hemoglobin, Deoxygenated
Below are MeSH descriptors whose meaning is more general than "Hemoglobin, Sickle".
Below are MeSH descriptors whose meaning is more specific than "Hemoglobin, Sickle".
This graph shows the total number of publications written about "Hemoglobin, Sickle" by people in Harvard Catalyst Profiles by year, and whether "Hemoglobin, Sickle" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 2 | 2 |
| 1994 | 1 | 1 | 2 |
| 1995 | 2 | 1 | 3 |
| 1996 | 0 | 2 | 2 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 0 | 4 | 4 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 3 | 5 |
Below are the most recent publications written about "Hemoglobin, Sickle" by people in Profiles.
-
Investigational curative gene therapy approaches to sickle cell disease. Blood Adv. 2021 12 14; 5(23):5452.
-
Increased Hemoglobin A1c Time in Range Reduces Adverse Health Outcomes in Older Adults With Diabetes. Diabetes Care. 2021 08; 44(8):1750-1756.
-
FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. Blood Adv. 2021 05 11; 5(9):2385-2390.
-
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021 May; 8(5):e323-e333.
-
MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease. Blood Adv. 2021 03 09; 5(5):1388-1402.
-
PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. J Med Chem. 2021 01 14; 64(1):326-342.
-
Kidney Function Decline among Black Patients with Sickle Cell Trait and Sickle Cell Disease: An Observational Cohort Study. J Am Soc Nephrol. 2020 02; 31(2):393-404.
-
High-throughput assessment of hemoglobin polymer in single red blood cells from sickle cell patients under controlled oxygen tension. Proc Natl Acad Sci U S A. 2019 12 10; 116(50):25236-25242.
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
-
Mendelian Randomization Analysis of Hemoglobin A1c as a Risk Factor for Coronary Artery Disease. Diabetes Care. 2019 07; 42(7):1202-1208.